AURO-CEFIXIME POWDER FOR SUSPENSION

Страна: Канада

Език: английски

Източник: Health Canada

Купи го сега

Активна съставка:

CEFIXIME

Предлага се от:

AURO PHARMA INC

АТС код:

J01DD08

INN (Международно Name):

CEFIXIME

дозиране:

100MG

Лекарствена форма:

POWDER FOR SUSPENSION

Композиция:

CEFIXIME 100MG

Начин на приложение:

ORAL

Броя в опаковка:

50ML/100ML

Вид предписание :

Prescription

Терапевтична област:

THIRD GENERATION CEPHALOSPORINS

Каталог на резюме:

Active ingredient group (AIG) number: 0122105001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2017-10-11

Данни за продукта

                                Page 1 of 33
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AURO-CEFIXIME
CEFIXIME FOR ORAL SUSPENSION, HOUSE STANDARD
100 MG / 5 ML, WHEN RECONSTITUTED
(as cefixime trihydrate)
ANTIBIOTIC
AURO PHARMA INC.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8,
Canada.
Date of Revision
:
November 5, 2020.
Submission Control No: 239750
Page 2 of 33
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
................................................................................3
INDICATIONS AND CLINICAL USE
......................................................................................3
CONTRAINDICATIONS
............................................................................................................4
WARNINGS AND PRECAUTIONS
..........................................................................................4
ADVERSE REACTIONS
............................................................................................................8
DRUG INTERACTIONS
..........................................................................................................10
DOSAGE AND ADMINISTRATION
......................................................................................11
OVERDOSAGE
.........................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................13
STORAGE AND STABILITY
..................................................................................................15
SPECIAL HANDLING INSTRUCTIONS
................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.....................................................16
PART II: SCIENTIFIC INFORMATION
................................................................................17
PHARMACEUTICAL INFORMATI
                                
                                Прочетете целия документ
                                
                            

Документи на други езици

Данни за продукта Данни за продукта френски 05-11-2020

Сигнали за търсене, свързани с този продукт

Преглед на историята на документите